Kathryn E. Falberg - 10 Jun 2025 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Director
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol
RCUS
Transactions as of
10 Jun 2025
Net transactions value
$0
Form type
4
Filing time
12 Jun 2025, 16:28:55 UTC
Previous filing
29 May 2025
Next filing
09 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
FALBERG KATHRYN E Director C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD /s/ Carolyn Tang, Attorney-in-Fact 12 Jun 2025 0001206977

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Award $0 +13,300 +24% $0.000000 68,600 10 Jun 2025 Direct F1
holding RCUS Common Stock 102,106 10 Jun 2025 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCUS Stock Option (Rights to Buy) Award $0 +38,300 $0.000000 38,300 10 Jun 2025 Common Stock 38,300 $10.02 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units that vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
F2 The option will vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.